Loader

Pathways

PathWhiz ID Pathway Meta Data

PW176004

Pw176004 View Pathway
metabolic

Clenbuterol Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Clenbuterol are predicted with biotransformer.

PW127903

Pw127903 View Pathway
drug action

Clevidipine Action Pathway

Homo sapiens
Clevidipine is a dihydropyridine L-type calcium channel blocker used to lower blood pressure when oral antihypertensive therapy is not feasible or not desirable. Clevidipine is used IV only and practitioners titrate this drug to lower blood pressure. It has a half-life of approximately one minute. It is rapidly inactivated by esterases. It can be found under the brand name Cleviprex. Clevidipine is a dihydropyridine L-type calcium channel blocker, highly selective for vascular, as opposed to myocardial, smooth muscle and, therefore, has little or no effect on myocardial contractility or cardiac conduction. Clevidipine belongs to a well-known class of drugs called dihydropyridine calcium channel antagonists. Clevidpine is the first third generation intravenous dihydropyridine calcium channel blocker. In vitro studies demonstrated that clevidipine acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in arterial dilation, widening of the artery opening, and without reducing central venous pressure or reducing cardiac output. Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. Some side effects of using clevidipine may include agitation, headache, lethargy, and twitching.

PW145613

Pw145613 View Pathway
drug action

Clevidipine Drug Metabolism Action Pathway

Homo sapiens

PW176005

Pw176005 View Pathway
metabolic

Clevidipine Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Clevidipine are predicted with biotransformer.

PW144880

Pw144880 View Pathway
drug action

Clidinium Drug Metabolism Action Pathway

Homo sapiens

PW000347

Pw000347 View Pathway
drug action

Clindamycin Action Pathway

Homo sapiens
Clindamycin is a natural antibiotic that produced by Streptomyces lincolnensis, which can be used for treating various bacterial infections by binding and inhibiting 23S portion of 50S subunit of ribosomes. Blocking the portion of ribosome can prevent transpeptidase reaction that will elongate peptide chain. Clindamycin has a bacteriostatic effect. It is used primarily to treat infections caused by susceptible anaerobic bacteria, including infections of the respiratory tract, skin and soft tissue infections, and peritonitis. In patients with hypersensitivity to penicillins, clindamycin may be used to treat infections caused by susceptible aerobic bacteria as well. Clindamycin may also be used in combination with chloroquine and quinine to treat malaria caused by Pasmodium falciparum. It is commonly used as a topical treatment for acne, and can be useful against some methicillin-resistant Staphylococcus aureus (MRSA) infections. Clindamycin may also be used to treat bone and joint infections, particularly those caused by Staphylococcus aureu

PW124195

Pw124195 View Pathway
drug action

Clindamycin Anti-Bacterial Action Pathway

Homo sapiens
Clindamycin is a semi-synthetic antibiotic that is related to lincomycin, which is a naturally occurring lincosamide from the organism Streptomyces lincolnensis. Clindamycin has largely replaced lincomycin as treatment as it has better properties. It can be taken orally in a capsule, as a cream, or an injection intravenously or intramuscularly. This antibiotic is used to treat a variety of infections including and not limited to bone or joint infections, strep throat, ear infections, pneumonia and acne. It mainly targets anaerobic bacteria, gram-positive cocci and bacilli and gram-negative bacilli meaning it has a very narrow spectrum of activity. Clindamycin's mechanism of action works by inhibiting the 23S rRNA which is a component of the 50S subunit of bacteria ribosomes. Clindamycin resembles the L-Pro-Met-tRNA which can bind within the subunit, but in Clindamycin's case, it inhibits further protein synthesis. It impedes both the assembly of the ribosomal subunits as well as initiation dissociation of peptidyl-tRNA from the ribosomes halting translation. Sometimes Clindamycin is administered with other antibiotics that can interrupt cell membranes allowing their entry, as well as clindamycin can also just be administered by itself and taken up in transporters.

PW145277

Pw145277 View Pathway
drug action

Clindamycin Drug Metabolism Action Pathway

Homo sapiens

PW145574

Pw145574 View Pathway
drug action

Clioquinol Drug Metabolism Action Pathway

Homo sapiens

PW127703

Pw127703 View Pathway
drug action

Clobazam Action Pathway

Homo sapiens
Clobazam is a benzodiazepine used as adjunct treatment in seizures associated with Lennox-Gastaut syndrome. It can be found under the brand names Onfi and Sympazan. Clobazam acts on the GABAA receptor to increase GABAnergic transmission, particularly chloride conductance in neurons. This causes neuronal hyperpolarization, resulting in an increase in the action potential threshold and reducing neuron firing frequency. Consequently, the general neuronal activity of the central nervous system is depressed; therefore, clobazam can be used to treat diseases caused by excessive excitatory action potentials. The exact mechanism of action for clobazam, a 1,5-benzodiazepine, is not fully understood but is thought to involve the potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor. Specifically, clobazam binds to the interface of the α2 and γ2-subunit of the GABAA receptor. It has a great affinity for the α2 subunit than the α1 subunit compared to other 1,4‐benzodiazepines. Binding of clobazam to the GABAA receptor causes chloride channels to open, resulting in an influx of chloride and thus hyperpolarization of neurons. Some side effects of using clobazam may include tiredness, drooling, and vomiting.